1
|
Afghani R, Hajimohammadi A, Azarhoush R, Kazemi-Nejad V, Yari B, Rezapour Esfahani M. Massive malignant pleural effusion due to lung adenocarcinoma in 13-year-old boy. Asian Cardiovasc Thorac Ann 2016; 24:389-92. [PMID: 26857800 DOI: 10.1177/0218492316633011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
A 13-year-old boy with no risk factors for lung cancer presented with a massive left-sided pleural effusion and a mediastinal shift on chest radiography and computed tomography. A chest tube drained bloody pleural fluid with an exudative pattern. A pleural biopsy and wedge biopsy of the left lower lobe revealed mucinous adenocarcinoma in the left lower lobe wedge biopsy and metastatic adenocarcinoma in the pleural biopsy. The patient is currently undergoing chemotherapy. Radiotherapy is planned after shrinkage of the tumor. Adenocarcinoma of the lung is very rarely seen in teenagers or children, especially in the absence of risk factors.
Collapse
Affiliation(s)
- Reza Afghani
- Department of Surgery, 5 Azar Hospital, Golestan University of Medical Sciences, Gorgan, Iran
| | - Amir Hajimohammadi
- Department of Surgery, 5 Azar Hospital, Golestan University of Medical Sciences, Gorgan, Iran
| | - Ramin Azarhoush
- Department of Pathology, 5 Azar Hospital, Golestan University of Medical Sciences, Gorgan, Iran
| | - Vahideh Kazemi-Nejad
- Department of Pathology, 5 Azar Hospital, Golestan University of Medical Sciences, Gorgan, Iran
| | - Behrouz Yari
- Department of Surgery, 5 Azar Hospital, Golestan University of Medical Sciences, Gorgan, Iran
| | - Mona Rezapour Esfahani
- Clinical Research Development Unit (CRDU), 5 Azar Hospital, Golestan University of Medical Sciences, Gorgan, Iran
| |
Collapse
|
2
|
Calvayrac O, Pradines A, Raymond-Letron I, Rouquette I, Bousquet E, Lauwers-Cances V, Filleron T, Cadranel J, Beau-Faller M, Casanova A, Milia J, Favre G, Mazières J. RhoB determines tumor aggressiveness in a murine EGFRL858R-induced adenocarcinoma model and is a potential prognostic biomarker for Lepidic lung cancer. Clin Cancer Res 2014; 20:6541-50. [PMID: 25320360 DOI: 10.1158/1078-0432.ccr-14-0506] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE A crucial event in lung adenocarcinoma progression is the switch from an aerogenous spread toward an infiltrating tumor. Loss of RhoB expression has been suggested to be critical for lung cancer invasion. Here, we tested RhoB expression as a prognostic biomarker in non-small cell lung cancer (NSCLC) with a special focus on lepidic pattern. EXPERIMENTAL DESIGN We analyzed RhoB expression using both IHC and RT-qPCR in two series of operated patients (n = 100 and 48, respectively) and in a series of advanced lepidic adenocarcinoma (n = 31) from different hospitals. Next, we examined the role of RhoB in lung cancer progression in transgenic mice that express inducible EGFR(L858R) crossed with Rhob null mice. RESULTS We identified that loss of RhoB expression was strongly associated with worse survival (P = 0.0001) and progression-free survival (P < 0.001) in the first series. We then confirmed these results after multivariate analyses of the second series. In the series of adenocarcinoma with lepidic features issued from a clinical trial (IFCT-0401), we showed that loss of RhoB expression was associated with higher aggressiveness of stage IV. Finally, we showed that EGFR(L858R)/Rhob(+/+) mice developed mainly diffuse lung tumors with a lepidic pattern, whereas EGFR(L858R)/Rhob(+/-) and EGFR(L858R)/Rhob(-/-) developed a greater number of tumors, and aggressive adenocarcinomas with invasive properties. CONCLUSIONS We showed that RhoB is not only a strong prognostic factor in NSCLC but it is also critical for the acquisition of an aggressive phenotype of adenocarcinoma.
Collapse
Affiliation(s)
- Olivier Calvayrac
- Inserm, UMR 1037-CRCT, Toulouse, France. Université Paul Sabatier, Toulouse, France. Institut Claudius Regaud, Toulouse, France
| | - Anne Pradines
- Inserm, UMR 1037-CRCT, Toulouse, France. Université Paul Sabatier, Toulouse, France. Institut Claudius Regaud, Toulouse, France
| | - Isabelle Raymond-Letron
- Université de Toulouse, UPS-INP-ENVT, UMS006, Laboratoire d'histopathologie, Toulouse, France
| | - Isabelle Rouquette
- Université Paul Sabatier, Toulouse, France. Hôpital Rangueil, Departement d'Anatomo-Cytopathologie, CHU Toulouse, Toulouse, France
| | - Emilie Bousquet
- Inserm, UMR 1037-CRCT, Toulouse, France. Université Paul Sabatier, Toulouse, France. Institut Claudius Regaud, Toulouse, France
| | | | | | - Jacques Cadranel
- Hôpital Tenon, Service de Pneumologie, AP-HP; GRC-UPMC 04 Theranoscan Paris 6 University, France
| | - Michèle Beau-Faller
- Hôpital de Hautepierre, Pôle de Biologie, Laboratoire de Biochimie et Biologie Moléculaire, CHU Strasbourg, Strasbourg cedex, France
| | - Anne Casanova
- Inserm, UMR 1037-CRCT, Toulouse, France. Université Paul Sabatier, Toulouse, France. Institut Claudius Regaud, Toulouse, France
| | - Julie Milia
- Université Paul Sabatier, Toulouse, France. Hôpital Larrey, Département de Pneumologie, CHU Toulouse, Toulouse, France
| | - Gilles Favre
- Inserm, UMR 1037-CRCT, Toulouse, France. Université Paul Sabatier, Toulouse, France. Institut Claudius Regaud, Toulouse, France.
| | - Julien Mazières
- Inserm, UMR 1037-CRCT, Toulouse, France. Université Paul Sabatier, Toulouse, France. Hôpital Larrey, Département de Pneumologie, CHU Toulouse, Toulouse, France.
| |
Collapse
|
3
|
Primary lung adenocarcinomas in children and adolescents treated for pediatric malignancies. J Thorac Oncol 2011; 5:1764-71. [PMID: 20975376 DOI: 10.1097/jto.0b013e3181f69f08] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
INTRODUCTION Primary lung adenocarcinoma is extremely rare in the pediatric age group. There have been anecdotal reports of lesions that are histologically indistinguishable from adult-type pulmonary adenocarcinoma in young patients after treatment for nonpulmonary cancers. Herein, we present clinical, histopathologic, and molecular data on eight such cases. METHODS Histopathologic evaluation of the tumors was performed according to the World Health Organization classification. Molecular studies for EGFR and KRAS mutations were performed on six patients with sufficient material. RESULTS All eight patients were never smokers, four males and four females. Median age at nonpulmonary cancer diagnosis was 14 years (range, 3-23 years). Pulmonary adenocarcinomas were diagnosed at a median age of 15 years (range, 10-24 years); tumors were 0.1 to 2.0 cm in size and in some cases coexisted with metastases from the original cancer. Retrospective review showed that in at least three patients, the nodules were radiographically present before chemotherapy. Of six patients whose tumors were tested for common EGFR and KRAS mutations, two were positive for the former and one for the latter. At a median follow-up of 11 months (range, 2-29 months), six patients remained well without lung nodules and two had additional small, peripheral lung nodules that have not been biopsied. CONCLUSIONS Pulmonary lesions found in young patients with pediatric cancers can be histologically indistinguishable from lung adenocarcinoma seen in adults, may display typical adenocarcinoma-associated mutations of EGFR and KRAS, and may precede the administration of cytotoxic chemotherapy.
Collapse
|
4
|
Félix L, Lantuejoul S, Jankowski A, Ferretti G. [Localized pure or mixed ground-glass lung opacities]. ACTA ACUST UNITED AC 2010; 90:1869-92. [PMID: 19953078 DOI: 10.1016/s0221-0363(09)73289-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Localized ground-glass opacities (GGOs) have been recently individualized and account for between 2.9% and 19% of all pulmonary nodules detected in high-risk patients included in CT screening series for lung cancer. These opacities, nodular, lobular or flat, correspond to benign lesions (localised infectious and inflammatory diseases, focal interstitial fibrosis, and atypical alveolar hyperplasia) or malignant lesions (bronchioloalveolar carcinoma, early-stage adenocarcinoma and sometimes metastases). Localized GGOs are more likely to be malignant than solid nodules and prognosis is related to the percentage of the ground-glass component. However, doubling time of pure localized malignant GGOs is longer than mixed localized malignant GGOs and even longer than the doubling time of solid malignant nodules. Therefore, localized GGOs warrant a dedicated diagnostic workup.
Collapse
Affiliation(s)
- L Félix
- Clinique Universitaire de Radiologie et Imagerie Médicale, Pôle d'Imagerie, CHU de Grenoble, France.
| | | | | | | |
Collapse
|
5
|
Inamura K, Togashi Y, Okui M, Ninomiya H, Hiramatsu M, Satoh Y, Okumura S, Nakagawa K, Shimoji T, Noda T, Ishikawa Y. HOXB2 as a Novel Prognostic Indicator for Stage I Lung Adenocarcinomas. J Thorac Oncol 2007; 2:802-7. [PMID: 17805056 DOI: 10.1097/jto.0b013e3181461987] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
BACKGROUND Outcomes of patients with lung adenocarcinomas can be predicted to some extent from the pathologic stage (p-stage). Although all attempts are made to fully remove cancer lesions, still a number of p-stage I patients without metastatic disease at the time of surgery develop recurrences and die of cancer. It is thus very important to identify p-stage I patients who are at risk of recurrence. METHODS Previously, using microdissected samples, we identified metastasis-related genes. Using real-time reverse-transcriptase polymerase chain reaction analysis, we investigated the transcriptional levels of the top metastasis-related genes using 96 independent test lung adenocarcinoma samples and investigated their correlations with the prognosis. RESULTS AND CONCLUSIONS We document evidence that p-stage I patients with HOXB2 up-regulation have a worse prognosis than those with HOXB2 down-regulation (p = 0.0065), whereas the HOXB2 status has no prognostic significance for p-stage II-IV patients. Comparing tumors and corresponding normal lung tissue, we confirmed HOXB2 up-regulated lesions to have much higher HOXB2 expression than the corresponding normal tissue. Confirmation with a larger number of samples is needed, with further research to clarify the molecular functions of HOXB2.
Collapse
Affiliation(s)
- Kentaro Inamura
- Department of Pathology, The Cancer Institute, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|